Anticancer agent 31
Anticancer agent 31 is a 1,3-diphenylurea quinoxaline derivative, and a anticancer agent. Anticancer agent 31 exhibits antitumor acitvity by arresting cell cycle at S phase and inducing apoptosis.
For research use only. We do not sell to patients.
- CAS No.: 2222930-72-3
- Formula: C28H21F2N5O2
- Molecular Weight:497.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Anticancer agent 31 (compound 2d) shows anticancer activity against human tumor cell lines (MGC-803, NCI-H460, T-24, HeLa, HepG2, and SMMC-7721) and displays lower cytotoxicity than 5-FU (HY-90006), Sorafenib.html" class="link-product" target="_blank">Sorafenib (HY-10201), and Cisplatin (HY-17394)[1].
Anticancer agent 31 (10, and 15 μM; 24 h) arrests cell cycle at S phase in MGC-803 cells, and induces tumor cells apoptosis[1].
Anticancer agent 31 (5, 10, and 15 μM; 24 h) reduces cell cycle regulatory protein CDK2, CDK4, cyclin A2, cyclin B1, and Apaf-1, anti-apoptotic protein Bcl-2; increases pro-apoptotic protein Bax protein level[1].
Anticancer agent 31 (5, 10 μM; 24 h) activates caspase-3 and caspase-9 by 73.6% and 65.3%, respectively; and also causes the loss of mitochondrial membrane potential (MMP) increase in JC-1 (HY-15534) detection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Normal cell line: HL-7702 and six human tumor cell lines: MGC-803, NCI-H460, T-24, HeLa, HepG2, and SMMC-7721
-
Concentration:
-
Incubation Time:
-
Result:Inhibited human tumor cell with IC50s of 9 μM (MGC-803), 12.3 μM (HeLa), 13.3 μM (NCI-H460), 30.4 μM (HepG2), 17.6 μM (SMMC-7721), 27.5 μM (T-24), respectively. Showed lowe cytotoxicity with an IC50 value of 80.9 μM, higher than the IC50s of tumor cell cells.
-
Cell Line:MGC-803
-
Concentration:0, 5, 10, 15 μM
-
Incubation Time:24 hours
-
Result:Decreased cell cycle regulatory protein (cyclin-dependent kinase (CDK)2, CDK4, cyclin A2, and cyclin B1) levels in a dose-dependent manner.
Suppressed anti-apoptotic protein Bcl-2 expression and up-regulated pro-apoptotic protein Bax level.
-
Cell Line:MGC-803
-
Concentration:0, 5, 10, 15 μM
-
Incubation Time:24 hours
-
Result:Caused MGC-803 cells arrest at S phase from 24.45% to 41.39% at 15 μM concentration.
Indicated that there was a interaction with DNA in the nucleus and affect DNA replication.
Increased the percentage of apoptotic tumor cells from 4.31% to 37.21%.
-
Cell Line:MGC-803
-
Concentration:5, 10 μM
-
Incubation Time:24 hours; JC-1 as the fluorescent probe
-
Result:Induced the loss of mitochondrial membrane potential (MMP) from 0.79% (control) to 37.4% (5 μM) and 81.4% (10 μM), respectively.
Chemical Information
-
CAS No. 2222930-72-3
-
Molecular Weight 497.50
-
Formula C28H21F2N5O2
-
SMILES
O=C(NC1=CC=CC(CNC2=NC3=CC(F)=C(C=C3N=C2)F)=C1)NC4=CC=C(C=C4)OC5=CC=CC=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 31 Related Classifications
HY-143302 Related Classifications
Powered by Bioz